The Food and Drug Adminstration's Antimicrobial Drugs Advisory Committee voted 11 to 4 that Achaogen Inc. (Nasdaq: AKAO) failed to provide substantial evidence of safety and effectiveness of plazomicin to treat bloodstream infections. Shares of the biopharmaceutical plummeted $3.64 to close at $11.06.
FDA committee says Achaogen failed to provide safety evidence
May 03, 2018 at 17:31 PM EDT
